Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surufatinib plus docetaxel as second-line therapy in EGFR wild-type non-squamous NSCLC
ChiCTR2100047313Phase 2Recruiting
- Sponsor
- Cancer Hospital of Guangxi Medical University
- Start
- Jun 2021
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of surufatinib and docetaxel in non-small cell lung cancer (NSCLC), sponsored by Cancer Hospital of Guangxi Medical University. Primary endpoint: Progression-Free Survival. Started Jun 2021; status: recruiting.
02
Drugs
surufatinibdocetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2100047313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100047313.